Alport syndrome: Its effects on the glomerular filtration barrier and implications for future treatment

Journal of Physiology

Volumn 592, Issue 18, 2014, Pages 4013-4023

  Savige, Judy ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; COLLAGEN TYPE 4; CONNECTIVE TISSUE GROWTH FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LAMININ; MATRIX METALLOPROTEINASE; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ALPORT SYNDROME; CAPILLARY ENDOTHELIUM; CELL ADHESION; CLINICAL FEATURE; COL4A5 GENE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; END STAGE RENAL DISEASE; GENE; GENE MUTATION; GLOMERULAR FILTRATION BARRIER; GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY TRANSPLANTATION; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE EPITHELIUM; MECHANICAL STRESS; MICROALBUMINURIA; NONHUMAN; PATHOGENESIS; PODOCYTE; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; PROTEINURIA; RENAL REPLACEMENT THERAPY; RENOVASCULAR HYPERTENSION; REVIEW; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; X CHROMOSOMAL INHERITANCE; ANIMAL; KIDNEY; METABOLISM; NEPHRITIS, HEREDITARY; PATHOPHYSIOLOGY;

ANIMALS; GLOMERULAR FILTRATION BARRIER; HUMANS; KIDNEY; NEPHRITIS, HEREDITARY;

EID: 84907809853     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2014.274449     Document Type: Review

References (78)

1. Abrahamson DR, Hudson BG, Stroganova L, Borza DB & St John PL. (2009). Cellular origins of type IV collagen networks in developing glomeruli. J Am Soc Nephrol 20, 1471-1479.
2. Abrahamson DR, Isom K, Roach E, Stroganova L, Zelenchuk A, Miner JH & St John PL. (2007). Laminin compensation in collagen alpha3(IV) knockout (Alport) glomeruli contributes to permeability defects. J Am Soc Nephrol 18, 2465-2472.
3. Baines RJ & Brunskill NJ. (2011). Tubular toxicity of proteinuria. Nat Rev Nephrol 7, 177-180.
4. Barker DF, Hostikka SL, Zhou J, Chow LT, Oliphant AR, Gerken SC, Gregory MC, Skolnick MH, Atkin CL & Tryggvason K. (1990). Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science 248, 1224-1227.
5. Bateman JF, Boot-Handford RP & Lamande SR. (2009). Genetic diseases of connective tissues: cellular and extracellular effects of ECM mutations. Nat Rev Genet 10, 173-183.
6. Bezakova G & Ruegg MA. (2003). New insights into the roles of agrin.Nat RevMol Cell Biol 4, 295-308.
7. Borza CM, Su Y, Chen X, Yu L, Mont S, Chetyrkin S, Voziyan P, Hudson BG, Billings PC, Jo H, Bennett JS, Degrado WF et al. (2012). Inhibition of integrin α2β1 ameliorates glomerular injury. J Am Soc Nephrol 23, 1027-1038.
8. Cheng S & Lovett DH. (2003). Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. Am J Pathol 162, 1937-1949.
9. Collar JE, Ladva S, Cairns TD & Cattell V. (2001). Red cell traverse through thin glomerular basement membranes. Kidney Int 59, 2069-2072.
10. Colville DJ & Savige J. (1997). Alport syndrome. A review of the ocular manifestations. Ophthalmic Genet 18, 161-173.
11. Comper WD, Haraldsson B & DeenWM. (2008). Resolved: normal glomeruli filter nephrotic levels of albumin. J Am Soc Nephrol 19, 427-432.
12. Cummins PM, von Offenberg Sweeney N, Killeen MT, Birney YA, Redmond EM & Cahill PA. (2007). Cyclic strain-mediated matrix metalloproteinase regulation within the vascular endothelium: a force to be reckoned with. Am J Physiol Heart Circ Physiol 292, H28-H42.
13. Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippin J,Mundel P, Pichler R, Griffin S, CouserWG & Shankland SJ. (2004). Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 65, 30-39.
14. Durvasula RV & Shankland SJ. (2005). Mechanical strain increases SPARC levels in podocytes: implications for glomerulosclerosis. Am J Physiol Renal Physiol 289, F577-F584.
15. Faul C, Asanuma K, Yanagida-Asanuma E, Kim K & Mundel P. (2007). Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol 17, 428-437.
16. Finkel RS, Flanigan KM,Wong B, Bonnemann C, Sampson J, Sweeney HL, Reha A, Northcutt VJ, Elfring G, Barth J & Peltz SW. (2013). Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PLoS One 8, e81302.
17. Giani M, Mastrangelo A, Villa R, Turolo S, Marra G, Tirelli AS, Hopfer H & Edefonti A. (2013). Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1. Pediatr Nephrol 28, 1837-1842.
18. Gross O, Beirowski B,Harvey SJ, McFadden C, Chen D, Tam S, Thorner PS, Smyth N, Addicks K, Bloch W, Ninomiya Y, Sado Y,Weber M & Vogel WF. (2004). DDR1-deficient mice show localized subepithelial GBM thickening with focal loss of slit diaphragms and proteinuria. Kidney Int 66, 102-111.
19. Gross O, Beirowski B, Koepke ML, Kuck J, Reiner M, Addicks K, Smyth N, Schulze-Lohoff E &Weber M. (2003). Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int 63, 438-446.
20. Gross O, Girgert R, Beirowski B, Kretzler M, Kang HG, Kruegel J, Miosge N, Busse AC, Segerer S, Voge LWF, Muller GA & Weber M. (2010). Loss of collagen-receptor DDR1 delays renal fibrosis in hereditary type IV collagen disease. Matrix Biol 29, 346-356.
21. Gross O, Licht C, Anders HJ, Hoppe B, Beck B, Tonshoff B, Hocker B,Wygoda S, Ehrich JH, Pape L, Konrad M, Rascher Wet al. (2012). Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 81, 494-501.
22. Gubler M, Levy M, Broyer M, Naizot C, Gonzales G, Perrin D & Habib R. (1981). Alport's syndrome. A report of 58 cases and a review of the literature. Am J Med 70, 493-505.
23. Gunwar S, Ballester F, Noelken ME, Sado Y, Ninomiya Y & Hudson BG. (1998). Glomerular basement membrane. Identification of a novel disulfide-cross-linked network of α3, α4, and α5 chains of type IV collagen and its implications for the pathogenesis of Alport syndrome. J Biol Chem 273, 8767-8775.
24. Harvey SJ & Miner JH. (2008). Revisiting the glomerular charge barrier in the molecular era. Curr Opin Nephrol Hypertens 17, 393-398.
25. Hausmann R, Kuppe C, Egger H, Schweda F, Knecht V, Elger M, Menzel S, Somers D, Braun G, Fuss A, Uhlig S, KrizW et al. (2010). Electrical forces determine glomerular permeability. J Am Soc Nephrol 21, 2053-2058.
26. Heikkila P, Parpala T, Lukkarinen O,Weber M & Tryggvason K. (1996). Adenovirus-mediated gene transfer into kidney glomeruli using an ex vivo and in vivo kidney perfusion system - first steps towards gene therapy of Alport syndrome. Gene Ther 3, 21-27.
27. Hertz JM, Thomassen M, Storey H & Flinter F. (2012). Clinical utility gene card for: Alport syndrome. Eur J Hum Genet 20.
28. Hood JC, Dowling J, Bertram JF, Young RJ, Huxtable C, Robinson W, & Savige J. (2002). Correlation of histopathological features and renal impairment in autosomal dominant Alport syndrome in Bull terriers. Nephrol Dial Transplant 17, 1897-1908.
29. Hudson BG. (2004). The molecular basis of Goodpasture and Alport syndromes: beacons for the discovery of the collagen IV family. J Am Soc Nephrol 15, 2514-2527.
30. Hudson BG, Tryggvason K, Sundaramoorthy M & Neilson EG. (2003). Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 348, 2543-2556.
31. Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A,Weber M, Gross O, Netzer KO, Flinter F, Pirson Y, Dahan K et al. (2003). X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a "European Community Alport Syndrome Concerted Action" study. J Am Soc Nephrol 14, 2603-2610.
32. Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A,Weber M, Gross O, Netzer KO, Flinter F, Pirson Y, Verellen C et al. (2000). X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol 11, 649-657.
33. Jarad G & Miner JH. (2009). Update on the glomerular filtration barrier. Curr Opin Nephrol Hypertens 18, 226-232.
34. Jeansson M & Haraldsson B. (2006). Morphological and functional evidence for an important role of the endothelial cell glycocalyx in the glomerular barrier. Am J Physiol Renal Physiol 290, F111-F116.
35. Kalluri R, Shield CF, Todd P, Hudson BG & Neilson EG. (1997). Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis. J Clin Invest 99, 2470-2478.
36. Kashtan CE, Atkin CL, Gregory MC & Michael AF. (1989). Identification of variant Alport phenotypes using an Alport-specific antibody probe. Kidney Int 36, 669-674.
37. Katayama K, Kawano M, Naito I, Ishikawa H, Sado Y, Asakawa N, Murata T, Oosugi K, Kiyohara M, Ishikawa E, Ito M & Nomura S. (2008). Irradiation prolongs survival of Alport mice. J Am Soc Nephrol 19, 1692-1700.
38. Kestila M, Lenkkeri U, Mannikko M, Lamerdin J, McCready P, Putaala H, Ruotsalainen V, Morita T, Nissinen M, Herva R, Kashtan CE, Peltonen L, et al.(1998). Positionally cloned gene for a novel glomerular protein - nephrin - is mutated in congenital nephrotic syndrome. Mol Cell 1, 575-582.
39. Koepke ML,Weber M, Schulze-Lohoff E, Beirowski B, Segerer S & Gross O. (2007). Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome. Nephrol Dial Transplant 22, 1062-1069.
40. Kriz W. (2008). Fenestrated glomerular capillaries are unique. J Am Soc Nephrol 19, 1439-1440.
41. Kruegel J, Rubel D & Gross O. (2013). Alport syndrome - insights from basic and clinical research. Nat Rev Nephrol 9, 170-178.
42. LeBleu V, Sugimoto H, Mundel TM, Gerami-Naini B, Finan E, Miller CA, Gattone VH 2nd, Lu L, Shield CF 3rd, Folkman J & Kalluri R. (2009). Stem cell therapies benefit Alport syndrome. J Am Soc Nephrol 20, 2359-2370.
43. Li Y, Cong R & Biemesderfer D. (2008). The COOH terminus of megalin regulates gene expression in opossum kidney proximal tubule cells. Am J Physiol Cell Physiol 295, C529-C537.
44. Lin X, Suh JH, Go G & Miner JH. (2013). Feasibility of repairing glomerular basement membrane defects in Alport syndrome. J Am Soc Nephrol.
45. Meehan DT, Delimont D, Cheung L, Zallocchi M, Sansom SC, Holzclaw JD, Rao V & Cosgrove D. (2009). Biomechanical strain causes maladaptive gene regulation, contributing to Alport glomerular disease. Kidney Int 76, 968-976.
46. Miner JH & Yurchenco PD. (2004). Laminin functions in tissue morphogenesis. Annu Rev Cell Dev Biol 20, 255-284.
47. Ninichuk V, Gross O, Reichel C, Khandoga A, Pawar RD, Ciubar R, Segerer S, Belemezova E, Radomska E, Luckow B, Perez de Lema G, Murphy PM et al. (2005). Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease. J Am Soc Nephrol 16, 977-985.
48. Noone D & Licht C. (2013). An update on the pathomechanisms and future therapies of Alport syndrome. Pediatr Nephrol 28, 1025-1036.
49. Ohlson M, Sorensson J & Haraldsson B. (2000). Glomerular size and charge selectivity in the rat as revealed by FITC-ficoll and albumin. Am J Physiol Renal Physiol 279, F84-F91.
50. Park CH & Maack T. (1984). Albumin absorption and catabolism by isolated perfused proximal convoluted tubules of the rabbit. J Clin Invest 73, 767-777.
51. Parkin JD, San Antonio JD, Pedchenko V, Hudson B, Jensen ST & Savige J. (2011). Mapping structural landmarks, ligand binding sites, and missense mutations to the collagen IV heterotrimers predicts major functional domains, novel interactions, and variation in phenotypes in inherited diseases affecting basement membranes. Hum Mutat 32, 127-143.
52. Parpala-Sparman T, Lukkarinen O, Heikkila P & Tryggvason K. (1999). A novel surgical organ perfusion method for effective ex vivo and in vivo gene transfer into renal glomerular cells. Urol Res 27, 97-102.
53. Pieri M, Stefanou C, Zaravinos A, Erguler K, Stylianou K, Lapathitis G, Karaiskos C, Savva I, Paraskeva R, Dweep H, Sticht C, Anastasiadou N et al. (2014). Evidence for Activation of the Unfolded Protein Response in collagen IV nephropathies. J Am Soc Nephrol 25, 260-275.
54. Pierson M, Cordier J, Hervouuet F & Rauber G. (1963). An unusual congenital and familial congenital malformative combination involving the eye and kidney. J GenetHum12, 184-213.
55. Prodromidi EI, Poulsom R, Jeffery R, Roufosse CA, Pollard PJ, Pusey CD & Cook HT. (2006). Bone marrow-derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome. Stem Cells 24, 2448-2455.
56. Rao VH, Meehan DT, Delimont D, Nakajima M,Wada T, Gratton MA & Cosgrove D. (2006). Role for macrophage metalloelastase in glomerular basement membrane damage associated with Alport syndrome. Am J Pathol 169, 32-46.
57. Roopenian DC & Akilesh S. (2007). FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7, 715-725.
58. Ryu M, Kulkarni OP, Radomska E, Miosge N, Gross O & Anders HJ. (2011). Bacterial CpG-DNA accelerates Alport glomerulosclerosis by inducing an M1 macrophage phenotype and tumor necrosis factor-α-mediated podocyte loss. Kidney Int 79, 189-198.
59. Savige J, Gregory M, Gross O, Kashtan C, Ding J & Flinter F. (2013). Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol 24, 364-375.
60. Savige J, Rana K, Tonna S, Buzza M, Dagher H &Wang YY. (2003). Thin basement membrane nephropathy. Kidney Int 64, 1169-1178.
61. Sayers R, Kalluri R, Rodgers KD, Shield CF, Meehan DT & Cosgrove D. (1999). Role for transforming growth factor-β1 in Alport renal disease progression. Kidney Int 56, 1662-1673.
62. Sayyed SG, Ryu M, Kulkarni OP, Schmid H, Lichtnekert J, Gruner S, Green L, Mattei P, Hartmann G & Anders HJ. (2011). An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes. Kidney Int 80, 68-78.
63. Smithies O. (2003).Why the kidney glomerulus does not clog: a gel permeation/diffusion hypothesis of renal function. Proc Natl Acad Sci U S A 100, 4108-4113.
64. Sugimoto H, Mundel TM, Sund M, Xie L, Cosgrove D & Kalluri R. (2006). Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc Natl Acad Sci U S A 103, 7321-7326.
65. Suh JH & Miner JH. (2013). The glomerular basement membrane as a barrier to albumin. Nat Rev Nephrol 9, 470-477.
66. Susztak K, Ciccone E, McCue P, Sharma K & Bottinger EP. (2005). Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoS Med 2, e45.
67. Takase O, Minto AW, Puri TS, Cunningham PN, Jacob A, Hayashi M & Quigg RJ. (2008). Inhibition of NF-κB-dependent Bcl-xL expression by clusterin promotes albumin-induced tubular cell apoptosis. Kidney Int 73, 567-577.
68. Tanaka M, Asada M, Higashi AY, Nakamura J, Oguchi A, Tomita M, Yamada S, Asada N, Takase M, Okuda T, Kawachi H, Economides AN et al. (2010). Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome. J Clin Invest 120, 768-777.
69. Tang Z, Lu B, Hatch E, Sacks SH & Sheerin NS (2009). C3a mediates epithelial-to-mesenchymal transition in proteinuric nephropathy. J Am Soc Nephrol 20, 593-603.
70. Tonna S,Wang YY,Wilson D, Rigby L, Tabone T, Cotton R & Savige J (2008). The R229Q mutation in NPHS2 may predispose to proteinuria in thin-basement-membrane nephropathy. Pediatr Nephrol 23, 2201-2207.
71. Vanacore R, Ham AJ, Voehler M, Sanders CR, Conrads TP, Veenstra TD, Sharpless KB, Dawson PE & Hudson BG (2009). A sulfilimine bond identified in collagen IV. Science 325, 1230-1234.
72. Vogel W, Brakebusch C, Fassler R, Alves F, Ruggiero F & Pawson T (2000). Discoidin domain receptor 1 is activated independently of β1 integrin. J Biol Chem 275, 5779-5784.
73. VogelW, Gish GD, Alves F & Pawson T (1997). The discoidin domain receptor tyrosine kinases are activated by collagen. Mol Cell 1, 13-23.
74. Wartiovaara J, Ofverstedt LG, Khoshnoodi J, Zhang J, Makela E, Sandin S, Ruotsalainen V, Cheng RH, Jalanko H, Skoglund U & Tryggvason K (2004). Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography. J Clin Invest 114, 1475-1483.
75. Wyss HM, Henderson JM, Byfield FJ, Bruggeman LA, Ding Y, Huang C, Suh JH, Franke T, Mele E, Polla KMR et al. (2011). Biophysical properties of normal and diseased renal glomeruli. Am J Physiol Cell Physiol 300, C397-C405
76. Zallocchi M, Johnson BM, Meehan DT, Delimont D & Cosgrove D (2013). α1β1integrin/Rac1-dependent mesangial invasion of glomerular capillaries in Alport syndrome. Am J Pathol 183, 1269-1280.
77. Zeisberg M, Khurana M, Rao VH, Cosgrove D, Rougier JP, Werner MC, Shield CF 3rd,Werb Z & Kalluri R (2006). Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease. PLoS Med 3, e100.
78. Zhou J & Reeders ST (1996). The alpha chains of type IV collagen. Contrib Nephrol 117, 80-104.